Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly EBITDA Margin came in at 11.16% in Q2 2026, down 169.0% YoY from 16.18% in Q2 2025, and down 18.27% on a QoQ basis from 13.66% in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 6 years of EBITDA Margin data on file, last reported at 11.16% in Q2 2026.
- Quarterly EBITDA Margin fell 169.0% year-over-year to 11.16% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 11.92% (up 1108.0% YoY) and the FY2025 annual result came in at 11.4%, up 2217.0% from the prior year.
- EBITDA Margin slipped to 11.16% in Q2 2026, from 13.66% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 46.82% in Q3 2022 to a low of 72.44% in Q1 2022.
- A 5-year average of 6.67% and a median of 2.09% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin soared 45461 bps — and 2023, when it slumped 6312 bps.
- Tracing KNSA's EBITDA Margin over 5 years: stood at 4.08% in 2022, then surged by 102 bps to 0.1% in 2023, then tumbled by 16315 bps to 15.75% in 2024, then jumped by 162 bps to 9.78% in 2025, then rose by 14 bps to 11.16% in 2026.
- The last three EBITDA Margin figures came in at 11.16% (Q2 2026), 13.66% (Q1 2026), and 9.78% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.07 Bn | 5.54 Bn | 220.03 Mn | 11.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.16% |
| Mar 31, 2026 | 13.66% |
| Dec 31, 2025 | 9.78% |
| Sep 30, 2025 | 13.28% |
| Jun 30, 2025 | 12.86% |
| Mar 31, 2025 | 9.63% |
| Dec 31, 2024 | -15.75% |
| Sep 30, 2024 | -8.61% |
| Jun 30, 2024 | -0.11% |
| Mar 31, 2024 | -20.71% |
| Dec 31, 2023 | 0.10% |
| Sep 30, 2023 | -16.30% |
| Jun 30, 2023 | -4.41% |
| Mar 31, 2023 | -23.16% |
| Dec 31, 2022 | -4.08% |
| Sep 30, 2022 | 46.82% |
| Jun 30, 2022 | -71.81% |
| Mar 31, 2022 | -72.44% |
| Dec 31, 2021 | -192.75% |
| Sep 30, 2021 | -253.55% |